We read with interest the results of the PREMIERE trial by Salem et al,1 a randomized controlled trial comparing transarterial chemoembolization (TACE) and yttrium-90 (Y90) transarterial radioembolization in patients with hepatocellular carcinoma (HCC) Barcelona Clinic Liver Cancer (BCLC) stages A or B disease.2 We congratulate the PREMIERE investigators in successfully performing such a challenging trial and furthering our understanding of this complex disease process. Patients with BCLC stages A and B disease are a heterogeneous population with treatment decisions impacted by cancer burden (number and size of tumors), hepatic function, and functional status.